ArticleERJ open research2026
SM17, an anti-interleukin-17 receptor B antibody, ameliorates pathogenesis of chronic rhinosinusitis with nasal polyps and idiopathic pulmonary fibrosis
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic respiratory diseases (CRDs), driven by dysregulated Th2/Th17 inflammation, represent a global health challenge with limited therapeutic options. Interleukin (IL)-25 has emerged as a key upstream regulator of both pathways, yet its exact role in CRDs' pathogenesis remains underexplored. Here, our aim is to evaluate the efficacies of SM17, a novel anti-IL-25 receptor (IL-17RB) antibody, in preclinical models of chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF). Methods: Eosinophil, peripheral blood mononuclear cell, primary macrophage and lung fibroblast cultures were utilised to define the mechanism of action for how SM17 could ameliorate CRSwNP and IPF related phenotypes Results: Conclusion: Our findings suggest that SM17 is a potential therapeutic agent to treat CRDs such as CRSwNP and IPF through Th2/Th17 dual modulation and antifibrotic function.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.